Asset Details
Do you wish to reserve the book?
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Do you wish to request the book?
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
2007
Overview
Sitagliptin (Januvia, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in type 2 diabetes therapy.
Publisher
Taylor & Francis Ltd,Dove Medical Press
Subject
/ Adenosine Deaminase Inhibitors
/ Animals
/ Blood Glucose - drug effects
/ Diabetes
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - drug therapy
/ Dipeptidyl Peptidase 4 - blood
/ Dipeptidyl-Peptidase IV Inhibitors
/ Glucagon-Like Peptide 1 - agonists
/ Glucagon-Like Peptide 1 - blood
/ Glucose
/ Glycoproteins - antagonists & inhibitors
/ Humans
/ Review
